MedTrace Logo

Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 Years

NCT01433926 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 114

Last updated 2011-09-14

No results posted yet for this study

Summary

Main objective: To analyze the clinical and biological characteristics of patients with disseminated breast cancer HER2 + treated with trastuzumab that have achieved a complete remission, partial or stable disease for a period exceeding 3 years.

In addition, there will be a sub-genetic analysis of patients in whom there is availability a sample of primary tumor preserved in paraffin. This sub-analysis will not interfere with routine clinical practice, as the tumor samples based on which will be held on genetic profile, have been preserved in paraffin was extracted from the primary tumor to the patient.

Conditions

  • HER-2 Positive Breast Cancer

Sponsors & Collaborators

  • Roche Farma, S.A

    collaborator INDUSTRY

  • Asociación para el Progreso de la Oncología en Málaga

    lead OTHER

Principal Investigators

  • Emilio Alba · Hospital Virgen de la Victoria

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2011-03-31
Completion
2011-09-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01433926 on ClinicalTrials.gov